Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia

Steven B. Heymsfield1*, M. Cristina Gonzalez2, Jianhua Lu1,3, Guang Jia1,3 and Jolene Zheng1

1Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA
2Post-Graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil
3Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA, USA

The first reports of accurate skeletal muscle mass measurement in human subjects appeared at about the same time as introduction of the sarcopenia concept in the late 1980s. Since then these methods, computed tomography and MRI, have been used to gain insights into older (i.e. anthropometry and urinary markers) and more recently developed and refined methods (ultrasound, bioimpedance analysis and dual-energy X-ray absorptiometry) of quantifying regional and total body skeletal muscle mass. The objective of this review is to describe the evolution of these methods and their continued development in the context of sarcopenia evaluation and treatment. Advances in these technologies are described with a focus on additional quantifiable measures that relate to muscle composition and ‘quality’. The integration of these collective evaluations with strength and physical performance indices is highlighted with linkages to evaluation of sarcopenia and the spectrum of related disorders such as sarcopenic obesity, cachexia and frailty. Our findings show that currently available methods and those in development are capable of non-invasively extending measures from solely ‘mass’ to quality evaluations that promise to close the gaps now recognised between skeletal muscle mass and muscle function, morbidity and mortality. As the largest tissue compartment in most adults, skeletal muscle mass and aspects of muscle composition can now be evaluated by a wide array of technologies that provide important new research and clinical opportunities aligned with the growing interest in the spectrum of conditions associated with sarcopenia.

Body composition: Nutritional assessment: Sarcopenia: Cachexia: Sarcopenic obesity

Skeletal muscle is the largest body compartment in most adults with the exception of an enlarged adipose tissue mass in the presence of obesity. The over 600 individual skeletal muscles provide a vast array of mechanical and structural functions while additionally participating in vital whole-body metabolic functions.

Skeletal muscles grow in size from birth onward, reaching peak mass in the third decade(1). Many factors determine an individual adult’s total body skeletal muscle mass and include their size (i.e. height)(2,3), magnitude of adiposity(4), race(1,5), genetic factors(6), activity(5), hormone(7) levels and diet(8). By the fourth decade populations(1,9) and individuals(10) begin to show a gradual loss in skeletal muscle mass and the rate of atrophy appears to accelerate beyond the seventh decade(1,9,11). These later years are associated with sarcopenia and related functional loss of skeletal muscle, often referred to as dynapenia(12), that together reflect skeletal muscle’s loss in mass, altered composition(13,14) and lowered functionality as defined by strength and

Abbreviations: ALST, appendicular lean soft tissue; BIA, bioimpedance analysis; CT, computed tomography; DCR, deuterated creatine; DXA, dual-energy X-ray absorptiometry; HU, Hounsfield units; IMAT, intermuscular adipose tissue; SEE, standard error of the estimate.

*Corresponding author: S. B. Heymsfield, email Steven.Heymsfield@pbrc.edu
physical performance. The senescence-related changes in skeletal muscle are, in turn, associated with adverse outcomes such as pathological bone fractures and even death\(^{(15)}\).

Measuring skeletal muscle mass, composition, strength and physical performance is thus a vital part of not only studying sarcopenia\(^{(16)}\), but also of growing importance in clinically evaluating and monitoring the greatly increasing population of ageing at-risk adults in most countries. Our report highlights aspects of evaluating these features of skeletal muscle and expands on earlier methodological\(^{(17)}\) and historical\(^{(2)}\) reviews.

While the main phenotypic feature of sarcopenia is loss of lean tissue, notably skeletal muscle, there is growing recognition that sarcopenia can co-exist in the presence of obesity\(^{(18)}\). A skeletal muscle compartment reduced in mass may thus be masked by the presence of excess fat. Diagnosing sarcopenic-obesity may thus include measures beyond that of skeletal muscle mass such as BMI and total body fat, topics that we will allude to in the review that follows. Loss of skeletal muscle also plays an important role in two other conditions, cachexia\(^{(19)}\) and frailty\(^{(20)}\), creating a spectrum of phenotypes and clinical conditions that encompass sarcopenia (Fig. 1).

**Skeletal muscle evaluation**

Two main factors, skeletal muscle mass and composition, are the main determinants of global muscle metabolic function, strength and physical performance. Vascular and neurological integrity are also essential components that ultimately contribute to a skeletal muscle’s metabolic and mechanical functionality\(^{(21)}\). The ‘quality’ of a skeletal muscle is a loosely defined concept that broadly includes aspects of anatomic structure, chemical composition and metabolic and mechanical performance\(^{(17)}\). Our review encompasses aspects of measuring skeletal muscle mass, composition and function in relation to the evaluation of individuals and groups for the presence of sarcopenia and related conditions.

Multiple methods of measuring skeletal muscle mass are available for research and clinical purposes that vary in cost, complexity and availability. The advantages and disadvantages of each method, reviewed in the following discussion, are summarised in Table 1.

**Anthropometry**

Searching for a measure of human working efficiency, Jindrich Matiegka reported in 1921 what was to become a classic anthropometric approach to quantifying skeletal muscle mass\(^{(22)}\). Matiegka’s method divided body weight into four parts: skeleton, skeletal muscle, skin plus subcutaneous adipose tissue and remainder. Crude measuring devices were used to quantify bone and extremity breadths and skinfold thickness. Estimated values were then incorporated along with the height and calculated surface area into Matiegka’s body composition prediction model. Seven decades later Martin *et al.* reported in 1990 one of the first whole-body anthropometric skeletal muscle prediction models by post-mortem calibration against twelve male subjects in the Brussels Cadaver Study (Table 2\(^{(23)}\)). Doupe *et al.* reported an updated version of Martin’s model in 1997\(^{(24)}\).

Others that followed Matiegka and later Martin were limited by a lack of reference standards for *in vivo* skeletal muscle mass measurement until the introduction of computed tomography (CT) by Hounsfield\(^{(25)}\). Since then CT, MRI and dual-energy X-ray absorptiometry (DXA) have all been used as the reference for developing anthropometric skeletal muscle mass prediction equations. Expanding on the Brussels Cadaver Study strategy, Lee *et al.*\(^{(17)}\) reported anthropometric skeletal muscle mass prediction equations developed in 244 adults using MRI as the reference (Table 2).

The most recent anthropometric approach was reported in 2014 by Al-Gindan *et al.*\(^{(26)}\) using total body skeletal muscle mass collected on 423 adults varying in age, sex, race and BMI using whole-body MRI as the reference. An additional 197 subjects served as a validation sample. The author’s main aim was to develop equations that incorporated commonly used measures that typically are collected in large population studies and surveys. The Al-Gindan prediction equations are summarised for men (derivation: \(R^2 0.76\), standard error of the estimate (SEE) 2.7 kg; validation: \(R^2 0.79\), SEE 2.7 kg) and women (derivation: \(R^2 0.58\), SEE 2.2 kg; validation: \(R^2 0.59\), SEE 2.1 kg) in Table 2.

Simple regional skeletal muscle estimation approaches are also available that are practical to apply in the clinical setting. For example, appendicular cross-sectional muscle plus bone areas can be derived using a combination of skinfold and circumference measurements (Table 2\(^{(27,28)}\)). Similar equations are also available that correct for bone inclusion within the skeletal muscle compartment\(^{(28)}\).

While anthropometry as a means of estimating skeletal muscle mass has several important advantages, use in the elderly poses problems not encountered in younger adults.
and children. These strengths and limitations of anthropometry are summarised in Table 1. Notably, anthropometric measurements are unable to discern the active contractile components from adipose and connective tissues embedded within the muscle compartment. These components may impact functional measures and account for the often-observed dissociation that occurs over time with ageing between skeletal muscle mass and function(29,30).

**Urinary markers**

Discovered in meat by Chevreul in 1835, creatine is a metabolite distributed primarily in skeletal muscle and to a lesser extent in brain and other tissues(31). Creatine undergoes non-enzymatic degradation to creatinine at a stable rate and this metabolic end-product is then excreted unchanged in urine. Urine collected over 24 h from subjects ingesting a meat-free diet can be analysed for creatinine and early workers assumed levels are directly proportional to skeletal muscle mass (1 g = about 20 kg)\(^{(32)}\). Forbes and Bruining in 1976 developed a urinary creatinine prediction equation with total body creatine pool size with mass

| Table 1. Advantages and disadvantages of skeletal muscle mass measurement methods |
|-----------------------------------|-----------------|------------------|------------------|
| **Method**                        | **Measurements**                  | **Advantages**                  | **Disadvantages**                  |
| Anthropometry                     | Skinfold thicknesses,             | Non-invasive and inexpensive    | Training required. Poor precision  |
|                                  | circumferences and linear          | Applicable in large surveys     | in obese subjects. Skinfold        |
|                                  | dimensions                        |                               | compressibility changes with       |
|                                  |                                |                               | age due to a loss in skin elastic  |
| Urinary metabolites              | 24-h creatinine and 3-methyl      | Non-invasive, safe, relatively   | Requires subject cooperation,     |
|                                  | histidine                        | inexpensive. Reflects muscle    | ideally collecting several        |
| Ultrasound                        | Muscle width and area             | safe, widely available, useful  | consecutive 24 h urine samples    |
| Bioimpedance Analysis             | Segmental impedance,              | Variable instrument cost, safe, | Technical skill required. Excess  |
|                                  | resistance and reactance;         | potentially portable, useful for | transducer pressure and               |
| Imaging                           | phase angle                       | long-term monitoring            | orientation can influence muscle  |
| CT                                | Cross-sectional muscle area,      | High resolution; three-dimensional| Radiation exposure, cost, subject  |
|                                  | muscle attenuation                | reconstruction; regional/whole-body; | size limitations                   |
| DXA                               | Lean soft tissue, fat and bone    | Wide availability; high precision; | Modest cost, size (weight and      |
|                                  | mineral content; other measures   | low radiation; regional and whole-body| height) limitations. Cannot    |
|                                  | of bone quality                   | measurements of the three        | specifically discern skeletal      |
| MRI                               | Cross-sectional muscle area       | High resolution; three-dimensional| Relatively high cost, subject     |
|                                  |                                | reconstruction; multiple measures of| size limitations                   |

SM, skeletal muscle; CT, computed tomography; CT#, linear attenuation coefficient; DXA, dual-energy X-ray absorptiometry.

Modified from references\(^{(17,27,56)}\).
Skeletal muscle contractile proteins, actin and myosin, are methylated after completion of peptide bond synthesis leading to the production of 3-methylhistidine. The 3-methylhistidine is released with protein catabolism and excreted unchanged in the urine. While urinary 3-methylhistidine collected over 24 h is typically used to evaluate the rate of myofibrillar protein breakdown, empirical skeletal muscle mass prediction equations have also been published (Table 2). Because of 3-methylhistidine’s complex metabolism, analytical costs and introduction of other competing methods, few workers today continue to use this metabolic end-product as a means of estimating skeletal muscle mass.

A limitation of urinary creatinine and 3-methylhistidine as markers of skeletal muscle mass is the requirement for dietary control and multiple 24-h urine collections that are applied together for optimum results. In the absence of other available methods, however, the cost of these approaches is minimal and there are no subject safety concerns as with some imaging methods. Additional research is needed on the use of DCR and serum creatinine for quantifying skeletal muscle mass.

Separate from measurement concerns, the two urinary markers conceptually reflect muscle cell mass rather than whole muscle that also includes embedded adipose tissue, connective tissues and extracellular fluid. Anthropometry, which measures whole muscle, may therefore give differing impressions of age-related chances than a marker such as urinary creatinine or DCR that capture muscle cell mass.

**Ultrasound**

Recent technological advances provide new opportunities for application of ultrasound in evaluating skeletal muscle mass. 

Recent technological advances provide new opportunities for application of ultrasound in evaluating skeletal muscle mass.
Sarcopenia assessment

Table 3. Magnetic resonance measurements and approaches for evaluating skeletal muscle that go beyond conventional volumetric rendering

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Comment</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMAT</td>
<td>Measured on conventional CT scan and T1-weighted images. IMAT linked with metabolic and clinical outcomes; IMAT-free SM proportionally decreased in the elderly</td>
<td>(74)</td>
</tr>
<tr>
<td>Short+ inversion recovery</td>
<td>Muscle oedema characterised by increased SM signal intensity</td>
<td>(102)</td>
</tr>
<tr>
<td>UTE</td>
<td>Visualisation of cortical bone, tendons, and ligaments. UTE imaging helps define mechanically-active portions of SM. Connective-tissue free SM decreased in the elderly</td>
<td>(103)</td>
</tr>
<tr>
<td>Magnetic resonance elastography</td>
<td>Evaluates SM viscoelastic properties/stiffness that may be adversely influenced by the presence of sarcopenia</td>
<td>(104)</td>
</tr>
<tr>
<td>Diffusion weighted imaging</td>
<td>Apparent diffusion coefficient gives a measure of muscle cell membrane integrity and perfusion through the microcirculation</td>
<td>(2, 102)</td>
</tr>
<tr>
<td>DTI</td>
<td>DTI measures anisotropy of water diffusion giving a measure of muscle cellular orientation and integrity. Measures such as fractional anisotropy give estimates of muscle microstructure</td>
<td>(102)</td>
</tr>
<tr>
<td>MRS</td>
<td>$^1$H MRS provides intracellular component measures such as IMCL. $^{31}$P MRS provides information on high-energy intermediates and related metabolic processes. $^{13}$C MRS gives information on SM triacylglycerol, glycogen and insulin resistance</td>
<td>(84, 105)</td>
</tr>
<tr>
<td>CEST</td>
<td>CEST tracks exchange of protons in amine (-NH$_2$) to bulk water. Visualisation of dynamic changes in free creatine in exercised muscle</td>
<td>(107)</td>
</tr>
</tbody>
</table>

IMAT, intermuscular adipose tissue; CT, computed tomography; UTE, ultra-short echo-time imaging; IMCL, intramyocellular lipid; SM, skeletal muscle; DTI, diffusion tensor imaging; MRS, magnetic resonance spectroscopy; CEST, chemical exchange saturation transfer.

Muscle mass and quality. Karl Dussik at the University of Vienna was the first to apply ultrasound methods in 1942 with early attempts at diagnosing brain tumours (38). Eight years later, George Ludwig at the United States Naval Research Institute further improved ultrasound methods for diagnosing the presence of gallstones (39). A piezoelectric crystal housed in the transducer probe produced high-frequency sound waves. The directed sound waves passed through the skin surface and then reflected off underlying anatomic structures, including skeletal muscle and bone interfaces. Returning sound waves, or echoes, were then captured by a receiver housed in the transducer probe. The same fundamental technology is in use today.

A mode ultrasound emerged in the 1960s as an alternative to skinfold calipers in evaluating subcutaneous adipose tissue layer thickness (40). A-mode systems provide an amplitude-modulated display that represents the intensity of returning echoes. This allows visualisation of various tissue interfaces and thereby measurement of fat and muscle ‘thickness’ at pre-defined anatomic sites. Commercial A-mode systems are in use today for measuring adipose tissue and skeletal muscle thickness at pre-defined anatomic sites (41). More recently B-mode systems provide a brightness-modulated display for echoes returning to the system transducer. B-mode systems display two-dimensional cross-sectional images of adipose tissue, skeletal muscle and bone structures. Newer ultrasound systems provide three-dimensional skeletal muscle images and thus selected total muscle volumes (42).

Two investigators at the University of Tokyo, Ikai and Fukunaga, were among the first to use ultrasound for measuring skeletal muscle cross-sectional areas in 1968 (43). Sanada et al. (44) measured skeletal muscle thickness in Japanese adults with ultrasound at several anatomic sites and the authors reported total body prediction equations using MRI as the reference. Abe et al. (45) recently reviewed previously published regional and total muscle mass ultrasound prediction equations using DXA as the reference criterion. The authors observed good correlations between DXA-derived muscle indices and corresponding ultrasound predictions ($R \geq 0.9$ and $P < 0.001$) in men and women with variable between-method significant bias, Sanada’s total muscle mass equation (Sanada et al. (44)) being the only one without non-significant bias. In another recent report, Loenneke et al. (46) suggested that skeletal muscle thickness measured at the anterior portion of the thigh can be used to track age-related changes in muscle size.

Ultrasound is increasingly being used to provide estimates of skeletal muscle quality. Ultrasound elastography, is a real-time method of visualising the distribution of skeletal muscle tissue strain and elastic modulus (47). Several ultrasound elastography methods are available that differ in the way tissue stress is applied and the method used to detect and reconstruct the displaced tissue image (47). The most common of these is strain ultrasound elastography in which one approach is to manually apply low-frequency tissue compression with the transducer probe. The resulting axial muscle tissue displacement (i.e. strain) can then be detected and quantified. Ageing and sarcopenia through associated changes in skeletal muscle quality (e.g. fibrosis) may result in biomechanical alterations (stiffness and loss of elasticity) that are detectable by ultrasound elastography.

Healthy muscle is echolucent or ‘dark’ as sound waves pass through the homogenous tissue and are reflected back only when they interact with fibrous structures such as vasculature and epimysium (48). As subjects age and develop sarcopenia, skeletal muscles increasingly have adipose tissue infiltration and fibrosis that lead to new sound reflection planes (49). These changes are accompanied by an increase in echogenicity, indicated as whiter muscles in ultrasonography, and the amount of ‘white’ and ‘dark’ muscle tissue of the sonographic images can be quantified by the degree of the echolucencies in human subjects (40,50). These effects are readily
evaluated using ultrasound imaging software. As a representative example, Watanabe et al.\(^a\) recently observed an inverse association between echo intensity and muscle strength in elderly men.

**Bioimpedance analysis**

Bioimpedance analysis (BIA) was pioneered in the 1950s and 1960s by Hoffer, Nyboer and Thomasset\(^b\). Today BIA is widely used in the study of human body composition as instruments are available, relatively inexpensive and analyses require minimal technician participation even when using research-grade systems. When a weak alternating current is applied across a limb the net conductivity when using research-grade systems. When a weak alternating current is applied across a limb the net conductivity reflects features of the traversed tissues\(^c\). Fluid and electrolyte-rich soft tissues, particularly skeletal muscle, are highly conductive by comparison with low-hydration tissues such as bone. All BIA systems exploit these tissue-specific conductivity differences to quantify body compartments such as skeletal muscle and adipose tissue.

Many system designs are available that range from single to multiple frequency, employ contact or gel-electrodes and that measure segmental or whole-body electrical pathways. All BIA systems measure impedance and/or its two components, resistance and reactance. These electrical measurements in turn can be incorporated into body composition prediction models that have empirical and/or theoretical underpinnings.

The most important advance in relation to skeletal muscle was reported by Organ et al.\(^d\). Organ et al. first described a six-electrode method for segmental BIA that allowed isolation of separate electrical properties of each extremity and the trunk. Several years later Tan et al.\(^e\) described construction of an eight-electrode BIA stand that included contact electrodes for the upright subject’s feet and hands. The impedance measures of the arm and leg could then be empirically calibrated to either DXA appendicular lean soft tissue mass (ALST), mainly skeletal muscle or MRI-derived skeletal muscle mass.

Brown et al.\(^f\) were the first to use BIA for estimating upper arm cross-sectional muscle and fat areas using CT as the reference. By 2000 Janssen et al.\(^g\) reported a whole-body skeletal muscle mass BIA prediction equation using MRI as the calibration method (Table 2).

Today several commercially available BIA systems are available, generalisations on accuracy and overall quality are not possible in the context of this review.

The strengths and limitations of BIA are summarised in Table 1. Since so many systems differing in design are available, generalisations on accuracy and overall quality are not possible in the context of this review. The features and supporting literature for each instrument should be scrutinised by the interested investigator or clinician. Of importance for all BIA systems is the presence of stable subject conditions at the time of measurement. Hydration, time of day and many other factors influence measured subject impedance values and meticulous adherence to manufacturer-specified conditions will ensure optimum results.

**Imaging**

The discovery of X-rays by Röntgen in 1895 transformed not only clinical medicine, but the field of body composition research as a whole. By 1942 Harold C. Stuart and P. Hill-Dwinell at Harvard evaluated muscle and fat ‘widths’ in growing children\(^h\). Godfrey Hounsfield at EMI in London revolutionised biomedical imaging with the introduction of the first functional CT scanner in 1975\(^i\) and not long after three publications on CT-measured skeletal muscle appeared between

Following up on a long series of important discoveries in physics, Raymond Damadian at SUNY Downstate introduced the first human MRI scanner in 1977(70). Studies of skeletal muscle biology proliferated in the 1980s as MRI system availability increased and investigators were able to scan subjects of all ages without the radiation concerns associated with CT. Working with a skeletal orientation related to osteoporosis, Mazess et al. first introduced the dual-photon absorptiometry concept in 1970 for bone evaluation in the presence of overlying soft tissues(71). Modern DXA systems that can also provide body composition estimates, including measures of skeletal muscle mass, were introduced in the late 1980s(72). Thus, within several decades the body composition field went from relying on such limited skeletal muscle mass estimation methods as anthropology and urinary creatinine excretion to advanced imaging methods such as CT, MRI and DXA. So far, ten Nobel Prizes have been awarded for development of imaging technology (Supplementary Table S1) that has had a major impact on sarcopenia research and clinical practice.

Computed tomography

CT was the first method introduced that could quantify whole-body and regional skeletal muscle mass with high accuracy. High-resolution cross-sectional images of pre-defined slice width can be analysed for each tissue, including skeletal muscle, using hand segmentation or automated software. Depending on the study, varying numbers of cross-sectional images can be combined to evaluate single muscle areas, volumes or whole-body skeletal muscle mass.

Each image pixel element, or pixel, is defined by a linear attenuation coefficient or CT# reported in Hounsfield units (HU). Water is internationally defined as 0 HU and air as −1000 HU. Adipose tissue has negative HU values, whereas skeletal muscle has positive HU values and these tissue X-ray attenuation differences can be exploited for analytical purposes during hand segmentation or by automated software.

The segmented CT scan provides measures of skeletal muscle area and multiple images at specified intervals can be used to derive regional or total volumes. Most investigators then calculate skeletal muscle mass from the measured volume as the product of volume and density, usually assumed as 1.04 g/cm(3)(11). With ageing, disuse or in pathological states increasing amounts of adipose tissue can be found within skeletal muscles, particularly of the lower extremities(73). This intermuscular adipose tissue (IMAT) can be quantified during the analysis and the analyst can then report the values for IMAT and IMAT-free skeletal muscle(74). At the molecular level, skeletal muscle is composed of proteins, water, electrolytes, lipids and small amounts of other compounds. Each of these molecular species has a known physical density and closely related attenuation and HU in the context of CT. Iron or fat infiltration of the liver raises and lowers hepatic HU values, respectively(75). These tissue attenuation effects can be exploited to quantify pathological changes within liver and other tissues. Similarly, a low tissue HU may be a marker of lipid or fluid infiltration in skeletal muscles that can be accompanied by functional changes(76). CT can thus provide through evaluated HU values a measure of skeletal muscle quality.

An advantage of CT is high-quality image reconstruction and stable attenuation values that aid in image segmentation and also provide a measure of tissue composition and quality. The radiation exposure of CT and relatively high-cost limit current applications mainly to research or in clinical settings that include CT scanning as part of routine patient care(77).

Differential absorptiometry

The availability of DXA systems, modest scan cost, low radiation exposure, short scan time and extensive information provided from each scan makes this approach the most widely used in sarcopenia research and clinical practice at the current time. The DXA approach provides estimates of three body compartments, lean soft tissue, bone mineral content and fat for the whole body and at least four regions, head, trunk, arms and legs. DXA also gives additional skeletal information of value in managing osteoporosis and other clinical conditions related to bone biology.

The lean soft tissue found in the arms and legs, referred to as ALST, has a high muscle content that constitutes a large fraction of total body skeletal muscle mass(78). Measured ALST can thus be used as a surrogate measure of skeletal muscle mass and can be calibrated against whole-body values derived by CT or MRI(79). The calibration process provides various prediction equations that can be used to derive total body skeletal muscle mass from the measured ALST value (Table 2).

Since DXA provides measures of regional and total body fat and bone, these components can also be used to evaluate the composite musculoskeletal system (i.e. muscle plus bone) and the level of adiposity. The pathological outcomes associated with sarcopenia often derive from combinations of the amount and quality of skeletal muscle, bone and fat present(80,81).

Magnetic resonance

The introduction of MRI in the 1980s expanded the initial use of CT as means of developing three-dimensional images of skeletal muscle, adipose tissue and other organs. This development is usually referred to as structural or anatomic imaging. The lack of subject exposure to ionising radiation positions MRI as the method of choice for quantifying skeletal muscle across the full lifespan. Most modern MRI scanners can accommodate obese subjects, particularly with the newer wide bore (70 cm) systems.

Water-fat imaging

As with CT, the traditional analysis approach is hand- or partially automated image segmentation. The hand-
segmentation approach to the whole-body MRI analysis is tedious, time-consuming and costly. Recent advances in water-fat imaging may soon allow automation of the segmentation process. Relaxation times and resonance frequencies are different for water and fat protons in their respective environments and these differences can be used to suppress the fat-bound signal. Two imaging approaches are available for exploiting these differences, relaxation-dependent or short inversion-time recovery and chemical shift-dependent or Dixon-based fat suppression. Karlsson et al. recently reported development of a two-point Dixon sequence automated water-fat segmentation method for evaluating total body and regional skeletal muscle volume. The authors showed excellent test–retest reliability (intraclass correlation coefficient 1.0, 95% agreement level −0.32 to 0.2 litres) and agreement with hand-segmented images of the lower leg (correlation R values 0.94–0.96) in a follow-up study using a 3T wide-bore MRI scanner and integrated quadrature body coil. Scan times were about 10 min and the results were evaluated for total body and eight regional skeletal muscle volumes. Shortening the whole-body analysis time is an important advance that could provide an opportunity for evaluating large and diverse samples for prediction model development expanding on the examples presented in Table 2.

In addition to total body and regional skeletal muscle mass, other features of skeletal muscle quality can also be evaluated with MRI and CT such as IMAT. Skeletal muscle in persons with sarcopenia is characterised by an enlarged IMAT component, notably in the lower extremities. Water-fat imaging has also been used to evaluate regional skeletal muscle fat infiltration, and as noted earlier, the CT# gives an indication of water and fat infiltration into skeletal muscles.

An important advance in the context of sarcopenia is a wide array of new magnetic resonance sequences and technology that have the potential to give new structural and functional information about individual muscles and whole-body skeletal muscle mass. These approaches are summarised in Table 3.

Integration with sarcopenia

Adjusting measurements for body size

The adult skeletal muscle compartment increases in size as a function of subject stature and adiposity. Quetelet in 1842 first showed that among adults body weight (W) increases as height (Ht) squared (W∝Ht²) (88). For most populations W/Ht² is independent of height and this observation forms a main basis of BMI. Van Itallie et al. in 1990 suggested that BMI be further divided into two height-normalised indices, fat mass index (FM/Ht²) and fat-free mass index (FFM/Ht²) (89). Support for this suggestion came later when Heymsfield et al. showed that adult fat-free mass also scales to height with powers of approximately 2 (90), thus making fat-free mass index independent of height. Baumgartner et al. working with ALST measured with dual-photon absorptiometry, extended Van Itallie’s concept by deriving ALST/Ht² as a sarcopenia index (87). Although it now appears as if adult skeletal muscle scales to height with powers slightly greater than 2, indices such as Baumgartner’s would likely only show weak correlations with height.

The growing interest in sarcopenia has led others to suggest additional indices. One explored in the recent Foundation for the National Institutes of Health sarcopenia guidelines is appendicular lean mass (i.e. ALST)/BMI. Other approaches, also based on DXA measurements, are more functional in design such as Siervo’s load-capacity model in which one calculated measure is trunk fat (load) divided by lower leg lean soft tissue (capacity). (88)

As with greater stature, increasing adiposity also leads to larger amounts of skeletal muscle mass. Forbes and more recently Thomas et al. developed quantitative models linking fat-free mass index (i.e. a proxy for muscle) and fat mass index. Thus, ‘cut-points’ for muscle indices need to consider subject adiposity when evaluating conditions such as sarcopenic obesity.

Mass v. function

Throughout our review we have endeavoured to identify methods that not only provide skeletal muscle mass estimates, but to go beyond by describing how these methods also reveal new information on muscle composition or quality. A vast literature now shows how skeletal muscle mass, function and outcomes are often uncoupled as people age. Moreover, in some cases body compartments such as fat mass are even stronger predictors of outcome measures in elderly subjects than skeletal muscle mass (91). These efforts are further clarifying the sarcopenia spectrum and the examination of the many reviewed muscle quality measures will likely improve our understanding of underlying mechanisms and, additionally, provide new clinically useful biomarkers of senescence-related changes in skeletal muscle.

Guideline development

Evaluating subjects for the presence of sarcopenia involves quantifying strength and physical performance. We briefly mention these aspects of muscle evaluation in the context of the present review. Additional details can be found in the reviews of Cooper et al. and Guralnik.

Strength evaluations typically focus on isolated muscle groups and include commonly used tests such as handgrip strength, knee flexion/extension, peak expiratory flow rate and maximum force/isotonic-isokinetic/arms–legs. Measures of performance collectively capture strength, coordination, aerobic fitness and balance. These tests typically include the Short Physical Performance Battery, usual gait speed, timed get-up-and-go test, stair climb power test and timed walk test (92). Often tests of skeletal muscle strength and physical performance will show relatively larger reductions over time in monitored elderly subjects and, importantly, demonstrate stronger associations with sarcopenia outcomes such as weakness, falls and fractures. While the
first phenotypic expression of sarcopenia by Rosenberg in 1988 was loss of ‘flesh’ or muscle mass(95). guidelines are increasingly focusing on functional measures as the first step in subject evaluations. The European Working Group of the Study of Older People (age >65 years) included a stepped algorithm with measures of performance (gait speed) and strength (grip) proceeding a measure of skeletal muscle mass(89) leading to the diagnosis of sarcopenia. More recently, the Foundation for the National Institutes Health recommended a screening algorithm designed for subjects presenting with poor physical function that starts with quantifying weakness (grip strength) followed by evaluation of muscle mass adequacy (DXA appendicular lean mass adjusted for BMI)(16,96–98).

Further refinements in sarcopenia guidelines are likely as measurement methods improve, additional outcome studies are conducted and other conditions such as sarcopenic obesity, cachexia and frailty are subject to similar critical algorithm development.

Conclusions

Methods of quantifying skeletal muscle mass continue to evolve providing a vast array of choices for use in research and clinical settings. The gap present between findings based on ‘mass’ and ‘functional’ measures likely can be closed in part with new approaches for evaluating skeletal muscle composition and quality. These translational approaches have the potential for identifying those at risk for developing sarcopenia and related disorders at an early stage during which interventions may be most effective in preventing morbidity and mortality.

Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0029665515000129.

Acknowledgements

The authors acknowledge the support of Ms Robin Post in manuscript preparation and Dr Neil Johannsen for his guidance on indicators of skeletal muscle strength and performance.

Financial Support

There was no external support for development of this manuscript.

Conflicts of Interest

S. B. H. is on the Medical Advisory Board of Tanita Corp., Tokyo, Japan. The company develops and manufactures bioimpedance analysis systems.

Authorship

S. B. H. drafted the manuscript outline and coordinated individual sections prepared by M. C. G., J. L., G. J. and J. Z. All the authors contributed to review and editing of the final report.

References

16. Studenski SA, Peters KW, Alley DE et al. (2014) The FNIH sarcopenia project: rationale, study description,
Sarcopenia assessment


86. McLean RR, Shaddell MD, Alley DE et al. (2014) Criteria for clinically relevant weakness and low lean mass and their...


